文献速递主动脉疾病

EVAR后持续性II型内漏致二次扩张动脉瘤壁的结构性萎缩

The structural atrophy of the aneurysm wall in secondary expanding aortic aneurysms with endoleak type II.
PubMed 文献 · J Vasc Surg · 2019-02-18

该研究对比了10例EVAR后持续性II型内漏伴二次扩张患者的瘤壁与42例AAA及13例对照主动脉,发现扩张瘤壁内膜中层变薄、细胞稀少、纤维组织减少、胶原亚型转换,基质金属蛋白酶表达上调,提示结构弱化。

要点

  • EVAR后持续性II型内漏二次扩张瘤壁呈萎缩和蛋白水解,提示结构弱化。
  • 瘤壁内膜中层显著变薄、细胞稀少,仅残留少量慢性炎症。
  • 纤维组织减少且胶原向不同亚型转换,基质金属蛋白酶表达显著上调。

核心结论

  • EVAR后持续性II型内漏的瘤囊形态以萎缩和蛋白水解为特征,提示结构弱化。

研究设计与样本

  • 研究纳入10例EVAR后经CT和超声造影诊断II型内漏伴二次扩张的患者,在腹膜后供血血管结扎时获取瘤囊样本。
  • 对照组织包括既往发表的42例AAA和13例对照主动脉。
  • 采用HE染色、CD3/4/31/68和Ki67免疫组化、TUNEL检测凋亡、RT-PCR和Western blot分析。

主要发现

  • EVAR后二次扩张在5年内达33.8%±30%。
  • 扩张后瘤壁内膜中层显著变薄伴细胞稀少,与AAA样本相比仅残留少量慢性炎症。
  • 巨噬细胞大量存在,基质金属蛋白酶表达显著上调,未见明显凋亡。
  • 与对照主动脉和AAA相比,纤维组织减少且胶原向不同亚型转换。
  • 在AAA中升高的转录因子VEGF、KLF4和BCL2在二次扩张后显著降低。

临床怎么用

  • 上述瘤壁萎缩和蛋白水解表现提示结构弱化,应考虑用于II型内漏的随访计划及潜在治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abdominal aortic aneurysm (AAA) has an age-dependent prevalence of 2% to 11% and is a leading cause of death in men aged >65 years if not treated surgically. Today, endovascular aneurysm repair (EVAR) is performed in up to 80% of elective cases and 60% of ruptured cases. Although EVAR improves perioperative, early, and midterm outcomes, it is associated with specific complications, especially endoleaks (ELs). Type II EL occurs in up to 30% of procedures; however, aneurysm sac expansion and rupture are rare, and currently nothing is known about the morphologic changes in this condition. In this study, we investigate the aneurysm wall morphology in secondary expanding human AAA samples after EVAR with persistent type II EL in comparison to nonaneurysmatic control aortic and AAA samples. METHODS: Samples were acquired from the aneurysm sac during retroperitoneal feeder vessel ligation in a cohort of 10 patients with secondary expansion after EVAR and type II EL diagnosed by computed tomography and contrast-enhanced ultrasound. Control tissues included 42 AAAs and 13 control aortae published previously. Hematoxylin and eosin staining and immunohistochemistry for CD3/4/31/68 and Ki67 were performed for morphologic analysis. Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) assays allowed quantification of apoptosis. Reverse transcription-polymerase chain reaction was used to quantify gene expression and Western blot to quantify collagen expression. RESULTS: Secondary expansion of 33.8% ± 30% during 5 years was seen after EVAR before reoperation. The aneurysm wall after expansion shows significant thinning of the intima-media layer accompanied by a scarcity of cells, with only a little chronic inflammation left compared with AAA samples. Macrophages are seen in abundance, and matrix metalloproteinase expression is significantly upregulated. Relevant apoptosis is not noticed. Fibrous tissue is reduced, and a collagen turnover to different subtypes is noted in comparison to nonaneurysmatic control aorta and AAA. In addition, the transcription factors vascular endothelial growth factor, Kruppel-like factor 4, and BCL2, elevated in AAA, are significantly reduced after secondary expansion. CONCLUSIONS: The aneurysm sac morphology after EVAR with persistent type II EL is characterized by atrophy and proteolysis suggestive of structural weakening. These results should be considered for the follow-up schedule as well as for the potential treatment of this most frequent EVAR complication.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Menges AL, Busch A, Reutersberg B, et al. The structural atrophy of the aneurysm wall in secondary expanding aortic aneurysms with endoleak type II. J Vasc Surg. 2019. PMID: 30792063. doi:10.1016/j.jvs.2018.10.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。